There were differences in the expression of immune protein in these samples, patient 4 and 7 had a more similar history and we saw an increase in Bcl-2, CD20, LAG3, MET (PanCK-), PTEN, AKT (PanCK−) after therapy, the protein expression of patient 8 is different however this patient was heavily pretreated and the samples are over 15 years apart and the tumor was TNBC (Additional file 1: Figure S3). This evidence concerns the gene BCL2 and neoplasm.